Innoviva (INVA) Receivables - Other (2010 - 2026)
Innoviva posted quarterly Receivables - Other of $58.6 million for Q1 2026, down 4.31% year-on-year from $61.3 million in Q1 2025, and little changed on a QoQ basis from $58.4 million in Q4 2025.
Innoviva (INVA) has 17 years of Receivables - Other data on file, last reported at $58.6 million in Q1 2026.
- For the quarter ending Q1 2026, Receivables - Other fell 4.31% year-over-year to $58.6 million; the trailing twelve-month figure through Mar 2026 stood at $58.6 million (down 4.31% YoY), and the FY2025 full-year result was $58.4 million, down 11.55% from the prior year.
- Receivables - Other for Q1 2026 stood at $58.6 million, roughly flat from $58.4 million in the prior quarter.
- Across five years, Receivables - Other topped out at $111.7 million in Q2 2022 and bottomed at $54.7 million in Q4 2022.
- The 5-year median for Receivables - Other is $63.4 million (2025), against an average of $67.2 million.
- The widest annual swing landed in 2022, when Receivables - Other gained 28.66%; it then slumped 41.15% in 2023.
- A 5-year view of Receivables - Other shows it stood at $54.7 million in 2022, then increased by 27.34% to $69.6 million in 2023, then decreased by 5.24% to $66.0 million in 2024, then slipped by 11.55% to $58.4 million in 2025, then advanced by 0.47% to $58.6 million in 2026.
- The last three Receivables - Other figures came in at $58.6 million (Q1 2026), $58.4 million (Q4 2025), and $63.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.62 Mn |
| Mar 31, 2026 | 58.62 Mn |
| Dec 31, 2025 | 58.35 Mn |
| Dec 31, 2025 | 58.35 Mn |
| Sep 30, 2025 | 63.35 Mn |
| Sep 30, 2025 | 63.35 Mn |
| Jun 30, 2025 | 67.34 Mn |
| Jun 30, 2025 | 67.34 Mn |
| Mar 31, 2025 | 61.26 Mn |
| Mar 31, 2025 | 61.26 Mn |
| Dec 31, 2024 | 65.97 Mn |
| Dec 31, 2024 | 65.97 Mn |
| Sep 30, 2024 | 60.51 Mn |
| Sep 30, 2024 | 60.51 Mn |
| Jun 30, 2024 | 67.20 Mn |
| Jun 30, 2024 | 67.20 Mn |
| Mar 31, 2024 | 61.87 Mn |
| Mar 31, 2024 | 61.87 Mn |
| Dec 31, 2023 | 69.62 Mn |
| Dec 31, 2023 | 69.62 Mn |
| Sep 30, 2023 | 57.01 Mn |
| Sep 30, 2023 | 57.01 Mn |
| Jun 30, 2023 | 65.72 Mn |
| Jun 30, 2023 | 65.72 Mn |
| Mar 31, 2023 | 60.31 Mn |
| Mar 31, 2023 | 60.31 Mn |
| Dec 31, 2022 | 54.67 Mn |
| Dec 31, 2022 | 54.67 Mn |
| Sep 30, 2022 | 65.61 Mn |
| Sep 30, 2022 | 65.61 Mn |
| Jun 30, 2022 | 111.68 Mn |
| Jun 30, 2022 | 111.68 Mn |
| Mar 31, 2022 | 93.52 Mn |
| Mar 31, 2022 | 93.52 Mn |
| Dec 31, 2021 | 42.49 Mn |
| Dec 31, 2021 | 42.49 Mn |
| Sep 30, 2021 | 101.27 Mn |
| Sep 30, 2021 | 101.27 Mn |
| Jun 30, 2021 | 104.26 Mn |
| Jun 30, 2021 | 104.26 Mn |
| Mar 31, 2021 | 88.97 Mn |
| Mar 31, 2021 | 88.97 Mn |
| Dec 31, 2020 | 93.93 Mn |
| Dec 31, 2020 | 93.93 Mn |
| Sep 30, 2020 | 92.15 Mn |
| Sep 30, 2020 | 92.15 Mn |
| Jun 30, 2020 | 82.40 Mn |
| Jun 30, 2020 | 82.40 Mn |
| Mar 31, 2020 | 82.13 Mn |
| Mar 31, 2020 | 82.13 Mn |
| Dec 31, 2019 | 79.43 Mn |
| Dec 31, 2019 | 79.43 Mn |
| Sep 30, 2019 | 11.20 Mn |
| Sep 30, 2019 | 11.20 Mn |
| Jun 30, 2019 | 67.56 Mn |
| Jun 30, 2019 | 67.56 Mn |
| Mar 31, 2019 | 58.64 Mn |
| Mar 31, 2019 | 58.64 Mn |
| Dec 31, 2018 | 83.29 Mn |
| Dec 31, 2018 | 83.29 Mn |
| Sep 30, 2018 | 3.60 Mn |
| Sep 30, 2018 | 3.60 Mn |
| Jun 30, 2018 | 70.54 Mn |
| Jun 30, 2018 | 70.54 Mn |
| Mar 31, 2018 | 55.84 Mn |
| Mar 31, 2018 | 55.84 Mn |
| Dec 31, 2017 | 200,000.00 |
| Dec 31, 2017 | 200,000.00 |
| Sep 30, 2017 | 51.88 Mn |
| Sep 30, 2017 | 51.88 Mn |
| Jun 30, 2017 | 61.80 Mn |
| Jun 30, 2017 | 61.80 Mn |
| Mar 31, 2017 | 43.73 Mn |
| Mar 31, 2017 | 43.73 Mn |
| Dec 31, 2016 | 46.85 Mn |
| Dec 31, 2016 | 46.85 Mn |
| Sep 30, 2016 | 36.62 Mn |
| Sep 30, 2016 | 36.62 Mn |
| Jun 30, 2016 | 35.82 Mn |
| Jun 30, 2016 | 35.82 Mn |
| Mar 31, 2016 | 27.54 Mn |
| Mar 31, 2016 | 27.54 Mn |
| Dec 31, 2015 | 26.23 Mn |
| Dec 31, 2015 | 26.23 Mn |
| Sep 30, 2015 | 16.95 Mn |
| Sep 30, 2015 | 16.95 Mn |
| Jun 30, 2015 | 14.00 Mn |
| Jun 30, 2015 | 14.00 Mn |
| Mar 31, 2015 | 10.24 Mn |
| Mar 31, 2015 | 10.24 Mn |
| Dec 31, 2014 | 10.55 Mn |
| Dec 31, 2014 | 10.55 Mn |
| Sep 30, 2014 | 4.01 Mn |
| Sep 30, 2014 | 4.01 Mn |
| Jun 30, 2014 | 3.47 Mn |
| Jun 30, 2014 | 3.47 Mn |
| Mar 31, 2014 | 865,000.00 |
| Mar 31, 2014 | 865,000.00 |
| Dec 31, 2013 | 3.18 Mn |
| Dec 31, 2013 | 3.18 Mn |
| Sep 30, 2013 | 517,000.00 |
| Sep 30, 2013 | 517,000.00 |
| Jun 30, 2013 | 337,000.00 |
| Jun 30, 2013 | 337,000.00 |
| Mar 31, 2013 | 2.22 Mn |
| Mar 31, 2013 | 2.22 Mn |
| Dec 31, 2012 | 1.06 Mn |
| Dec 31, 2012 | 1.06 Mn |
| Sep 30, 2012 | 100,000.00 |
| Sep 30, 2012 | 100,000.00 |
| Jun 30, 2012 | 94,000.00 |
| Jun 30, 2012 | 94,000.00 |
| Mar 31, 2012 | 63,000.00 |
| Mar 31, 2012 | 63,000.00 |
| Dec 31, 2011 | 223,000.00 |
| Dec 31, 2011 | 223,000.00 |
| Sep 30, 2011 | 63,000.00 |
| Sep 30, 2011 | 63,000.00 |
| Jun 30, 2011 | 32,000.00 |
| Jun 30, 2011 | 32,000.00 |
| Dec 31, 2010 | 194,000.00 |
| Dec 31, 2010 | 194,000.00 |